- Home
- LQDA vs EU Comparison
LQDA vs EU Comparison
Compare LQDA & EU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LQDA
- EU
- Stock Information
- Founded
- LQDA 2004
- EU 2009
- Country
- LQDA United States
- EU United States
- Employees
- LQDA N/A
- EU N/A
- Industry
- LQDA Biotechnology: Pharmaceutical Preparations
- EU Other Metals and Minerals
- Sector
- LQDA Health Care
- EU Basic Materials
- Exchange
- LQDA Nasdaq
- EU Nasdaq
- Market Cap
- LQDA 856.5M
- EU 724.1M
- IPO Year
- LQDA 2018
- EU N/A
- Fundamental
- Price
- LQDA $10.65
- EU $3.85
- Analyst Decision
- LQDA Strong Buy
- EU Strong Buy
- Analyst Count
- LQDA 8
- EU 2
- Target Price
- LQDA $27.14
- EU $6.50
- AVG Volume (30 Days)
- LQDA 773.7K
- EU 1.2M
- Earning Date
- LQDA 11-13-2024
- EU 11-14-2024
- Dividend Yield
- LQDA N/A
- EU N/A
- EPS Growth
- LQDA N/A
- EU N/A
- EPS
- LQDA N/A
- EU N/A
- Revenue
- LQDA $15,610,000.00
- EU $44,972,063.00
- Revenue This Year
- LQDA N/A
- EU N/A
- Revenue Next Year
- LQDA $227.73
- EU $109.91
- P/E Ratio
- LQDA N/A
- EU N/A
- Revenue Growth
- LQDA N/A
- EU N/A
- 52 Week Low
- LQDA $6.69
- EU $3.02
- 52 Week High
- LQDA $16.99
- EU $5.05
- Technical
- Relative Strength Index (RSI)
- LQDA 52.84
- EU 50.58
- Support Level
- LQDA $9.93
- EU $3.47
- Resistance Level
- LQDA $10.95
- EU $4.00
- Average True Range (ATR)
- LQDA 0.45
- EU 0.25
- MACD
- LQDA -0.02
- EU 0.03
- Stochastic Oscillator
- LQDA 67.14
- EU 64.52
About LQDA Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
About EU enCore Energy Corp.
enCore Energy Corp together with its subsidiary, is engaged in the acquisition and exploration of resource properties. The holds a portfolio of uranium assets located in New Mexico, South Dakota, Wyoming, Texas, Utah, Colorado, and Arizona in the USA, and is advancing its properties with a focus on utilizing in-situ recovery. The company's material properties and projects are the Rosita Project located in Texas, the Alta Mesa Uranium project in Texas, the Crownpoint and Hosta Butte Uranium Project located in New Mexico, the Dewey Burdock Project located in South Dakota, and the Gas Hills Project located in Wyoming.